Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Regeneron's Hearing Loss Gene Therapy Shows Promise, Paving Way for FDA Submission

Regeneron's Hearing Loss Gene Therapy Shows Promise, Paving Way for FDA Submission

Regeneron Pharmaceuticals is poised to seek FDA approval for a groundbreaking gene therapy targeting a rare, genetic form of deafness, following encouraging results from a small clinical trial. The therapy, code-named DB-OTO, has demonstrated significant improvements in hearing for children with a specific gene mutation, potentially offering an alternative to cochlear implants.

NoahAI News10/12/2025
Trump Administration Initiates Layoffs at HHS Amid Government Shutdown

Trump Administration Initiates Layoffs at HHS Amid Government Shutdown

The Trump administration has taken the unprecedented step of firing federal employees at the Department of Health and Human Services (HHS) during the ongoing government shutdown, marking a significant escalation in normal shutdown procedures. This move has sent shockwaves through the federal workforce and drawn sharp criticism from Democratic lawmakers.

NoahAI News10/11/2025
Pharmaceutical Industry Faces Wave of Layoffs and Restructuring Amid Shifting Market Dynamics

Pharmaceutical Industry Faces Wave of Layoffs and Restructuring Amid Shifting Market Dynamics

The pharmaceutical industry is experiencing a significant period of transition, with numerous companies announcing major layoffs and restructuring efforts in the latter half of 2025. These changes come as firms grapple with evolving market conditions, pipeline challenges, and the need to reallocate resources towards high-priority programs.

NoahAI News10/11/2025
BMS Expands Cell Therapy Portfolio with $1.5B Orbital Therapeutics Acquisition

BMS Expands Cell Therapy Portfolio with $1.5B Orbital Therapeutics Acquisition

Bristol Myers Squibb (BMS) has announced a $1.5 billion acquisition of Orbital Therapeutics, signaling a significant expansion of its cell therapy capabilities. The deal, which focuses on Orbital's innovative RNA-based technologies, aims to bolster BMS's position in the rapidly evolving field of cell therapy, particularly for autoimmune diseases.

NoahAI News10/11/2025
AviadoBio Secures $413M Option Deal with Chinese Biotech for Rare Eye Disease Gene Therapy

AviadoBio Secures $413M Option Deal with Chinese Biotech for Rare Eye Disease Gene Therapy

AviadoBio, a London-based pharmaceutical company, has entered into a significant agreement with UgeneX Therapeutics, a Chinese biotech firm, for an investigational gene therapy targeting rare eye conditions. The deal, announced on October 10, 2025, could be worth up to $413 million and marks another instance of Western companies turning to China for novel therapies.

NoahAI News10/11/2025
Bristol Myers Squibb Expands Cell Therapy Portfolio with $1.5B Orbital Therapeutics Acquisition

Bristol Myers Squibb Expands Cell Therapy Portfolio with $1.5B Orbital Therapeutics Acquisition

Bristol Myers Squibb (BMS) has announced its acquisition of Orbital Therapeutics for $1.5 billion, marking a significant expansion into the rapidly evolving field of "in vivo" cell therapies. This strategic move positions BMS at the forefront of innovative treatments for inflammatory conditions and autoimmune diseases.

NoahAI News10/11/2025
Zimmer Biomet Expands Orthopedic Portfolio with New Paragon 28 Devices

Zimmer Biomet Expands Orthopedic Portfolio with New Paragon 28 Devices

Zimmer Biomet has launched two new orthopedic devices developed by Paragon 28, the foot and ankle specialist it acquired for $1.1 billion earlier this year. The introduction of these products marks a significant step in Zimmer's strategy to maintain Paragon's double-digit growth and expand its sports medicine, extremities, and trauma (SET) business.

NoahAI News10/11/2025
Swiss Auto-Injector Specialist Ypsomed Invests $248M in First U.S. Manufacturing Facility

Swiss Auto-Injector Specialist Ypsomed Invests $248M in First U.S. Manufacturing Facility

Ypsomed, a leading Swiss auto-injector specialist, has announced plans to invest 200 million Swiss francs ($248 million) to construct its first manufacturing facility in the United States. The new plant, to be located in Holly Springs, North Carolina, marks a significant milestone in the company's global expansion strategy and reinforces its commitment to serving the growing U.S. market for self-injection devices.

NoahAI News10/11/2025
Cabaletta's CAR-T Therapy Shows Promise in Autoimmune Disease Treatment Without Preconditioning

Cabaletta's CAR-T Therapy Shows Promise in Autoimmune Disease Treatment Without Preconditioning

Cabaletta Bio has reported encouraging results from its phase 1/2 RESET-PV trial, testing resecabtagene autoleucel (rese-cel) in patients with pemphigus vulgaris, a rare autoimmune disease. The therapy successfully eliminated overreactive B cells in two patients without the need for preconditioning chemotherapy, marking a significant advancement in the field of autoimmune treatments.

NoahAI News10/11/2025
Robotic Surgery Advancements: AI Integration and New Applications in Ophthalmology and Neurosurgery

Robotic Surgery Advancements: AI Integration and New Applications in Ophthalmology and Neurosurgery

Significant developments in robotic surgery systems are paving the way for enhanced precision and expanded applications across multiple medical specialties. Recent announcements from key players in the field highlight the integration of artificial intelligence, improvements in imaging capabilities, and novel applications in ophthalmology and neurosurgery.

NoahAI News10/11/2025
Novo Nordisk Discontinues Cell Therapy Research, Shifts Focus Amid Major Restructuring

Novo Nordisk Discontinues Cell Therapy Research, Shifts Focus Amid Major Restructuring

Novo Nordisk, the Danish pharmaceutical giant, has announced the closure of its cell therapy unit as part of a significant company-wide restructuring effort. This move marks the end of the company's work on potential breakthrough treatments, including a possible cure for Type 1 diabetes.

NoahAI News10/11/2025
J&J in Talks to Acquire Immunology Partner Protagonist Therapeutics

J&J in Talks to Acquire Immunology Partner Protagonist Therapeutics

Johnson & Johnson (J&J) is reportedly in discussions to acquire its immunology partner, Protagonist Therapeutics, in a move that could significantly bolster its pharmaceutical portfolio. The potential deal, as reported by The Wall Street Journal, is expected to value Protagonist well above its current market capitalization of over $4 billion.

NoahAI News10/11/2025
«1...434445...67»